3 assets in Pancreatic Neuroendocrine Tumor G1

Therapeutic assets addressing Pancreatic Neuroendocrine Tumor G1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Oxodotreotide Pancreatic Neuroendocrine Tumor G1	Vanderbilt-Ingram Cancer Center	P4	BB (65)
Everolimus Pancreatic Neuroendocrine Tumor G1	AC Camargo Cancer Center	P2	B (57)
[212pb] vmt-α-net Pancreatic Neuroendocrine Tumor G1	David Bushnell	Early P1	C (39)